Back to results
US 2008/0175900 A1Published application
Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
AssigneeWyeth
InventorsMahesh K. KRISHNAN, Mohamed GHORAB, Rolland W. CARSON, Patricia Carson, Shamim HASAN, Arwinder NAGI
Life of this patent
Estimating the term…
Abstract
The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.
Claims63
A liquid or semi-solid pharmaceutical formulation comprising:
- (a) a first carrier component comprising from about 10% to about 99.99% by weight of said pharmaceutical formulation;
- (b) an optional second carrier component, when present, comprising up to about 70% by weight of said pharmaceutical formulation;
- (c) an optional emulsifying/solubilizing component, when present, comprising from about 0.01% to about 30% by weight of said pharmaceutical formulation;
- (d) an optional anti-crystallization/solubilizing component, when present, comprising from about 0.01% to about 30% by weight of said pharmaceutical formulation;
- and
- (e) an active pharmacological agent comprising from about 0.01% to about 80% of said pharmaceutical formulation, wherein said active pharmacological agent comprises the anhydrate crystal form (Form B) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol.
3 more elements
A liquid or semi-solid pharmaceutical formulation comprising:
- (a) a first carrier component comprising from about 10% to about 99.99% by weight of said pharmaceutical formulation;
- (b) an optional second carrier component, when present, comprising up to about 70% by weight of said pharmaceutical formulation;
- (c) an emulsifying/solubilizing component comprising from about 0.01% to about 30% by weight of said pharmaceutical formulation;
- (d) an optional anti-crystallization/solubilizing component, when present, comprising from about 0.01% to about 30% by weight of said pharmaceutical formulation;
- and
- (e) an active pharmacological agent comprising from about 0.01% to about 80% of said pharmaceutical formulation, wherein said active pharmacological agent comprises the anhydrate crystal form (Form B) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol.
3 more elements
A solid pharmaceutical formulation comprising:
- (a) a first diluent/filler component comprising from about 30% to about 95% by weight of said formulation;
- (b) an optional second diluent/filler component, when present, comprising up to about 40% by weight of said pharmaceutical formulation;
- (c) a disintegrant component comprising from about 0.01% to about 30% by weight of said pharmaceutical formulation;
- (d) a binder component comprising from about 0.01% to about 20% by weight of said pharmaceutical formulation;
- (e) a wetting agent component comprising from about 0.01% to about 20% by weight of said pharmaceutical formulation;
- (f) an optional lubricant component, when present, comprising from about 0.01% to about 10% by weight of said pharmaceutical formulation;
- and
- (g) an active pharmacological agent comprising from about 0.01% to about 80% by weight of said pharmaceutical formulation, wherein said active pharmacological agent comprises the anhydrate crystal form (Form B) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol.
5 more elements
Dependencies are inferred from the claim text.